| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-13 11:48:34 UTC |
|---|
| Update Date | 2023-02-21 17:29:03 UTC |
|---|
| HMDB ID | HMDB0041931 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | 3,4-Methylenedioxyamphetamine |
|---|
| Description | An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]; In 1970, the Controlled Substances Act was enacted in the United States, placing MDA into Schedule I. It is similarly controlled in other nations. In Canada MDA is a Schedule III drug. Internationally, MDA is a Schedule I drug under the Convention on Psychotropic Substances. Many similar unscheduled MDxx chemicals can be prosecuted under the Federal Analog Act. MDA (3,4-methylenedioxyamphetamine), also known as tenamfetamine (INN), is a psychedelic and entactogenic drug of the phenethylamine and amphetamine chemical classes. It is mainly used as a recreational drug, an entheogen, and a tool in use to supplement various types of practices for transcendence, including in meditation, psychonautics, and as an agent in psychedelic psychotherapy. It was first synthesized by G. Mannish and W. Jacobson in 1910. There are about 20 different synthetic routes described in the literature for its preparation. |
|---|
| Structure | InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| (RS)-3,4-(Methylenedioxy)methamphetamine | HMDB | | 1-(1,3-Benzodioxol-5-yl)-N-methyl-2-propanamine | HMDB | | 1-(1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine | HMDB | | 3,4-Methylenedioxymethamphetamine | HMDB | | DL-(3,4-Methylenedioxy)methamphetamine | HMDB | | MDMA | HMDB | | N,alpha-Dimethyl-1,3-benzodioxole-5-ethanamine | HMDB | | N-Methyl-3,4-methylenedioxyamphetamine | HMDB | | 3,4 Methylenedioxyamphetamine | HMDB | | 3,4-Methylenedioxyamphetamine | MeSH |
|
|---|
| Chemical Formula | C10H13NO2 |
|---|
| Average Molecular Weight | 179.2157 |
|---|
| Monoisotopic Molecular Weight | 179.094628665 |
|---|
| IUPAC Name | 1-(2H-1,3-benzodioxol-5-yl)propan-2-amine |
|---|
| Traditional Name | 3,4-methylenedioxyamphetamine |
|---|
| CAS Registry Number | 4764-17-4 |
|---|
| SMILES | CC(N)CC1=CC2=C(OCO2)C=C1 |
|---|
| InChI Identifier | InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3 |
|---|
| InChI Key | NGBBVGZWCFBOGO-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzodioxoles. These are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzodioxoles |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Benzodioxoles |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzodioxole
- Aralkylamine
- Benzenoid
- Oxacycle
- Acetal
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Primary amine
- Organooxygen compound
- Organonitrogen compound
- Primary aliphatic amine
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | 1.64 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 2.53 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.2315 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.38 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 104.7 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1071.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 316.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 125.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 184.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 76.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 312.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 350.1 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 299.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 825.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 319.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 902.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 231.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 264.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 448.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 337.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 104.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 3,4-Methylenedioxyamphetamine,1TMS,isomer #1 | CC(CC1=CC=C2OCOC2=C1)N[Si](C)(C)C | 1644.3 | Semi standard non polar | 33892256 | | 3,4-Methylenedioxyamphetamine,1TMS,isomer #1 | CC(CC1=CC=C2OCOC2=C1)N[Si](C)(C)C | 1639.3 | Standard non polar | 33892256 | | 3,4-Methylenedioxyamphetamine,2TMS,isomer #1 | CC(CC1=CC=C2OCOC2=C1)N([Si](C)(C)C)[Si](C)(C)C | 1853.0 | Semi standard non polar | 33892256 | | 3,4-Methylenedioxyamphetamine,2TMS,isomer #1 | CC(CC1=CC=C2OCOC2=C1)N([Si](C)(C)C)[Si](C)(C)C | 1860.6 | Standard non polar | 33892256 | | 3,4-Methylenedioxyamphetamine,1TBDMS,isomer #1 | CC(CC1=CC=C2OCOC2=C1)N[Si](C)(C)C(C)(C)C | 1887.9 | Semi standard non polar | 33892256 | | 3,4-Methylenedioxyamphetamine,1TBDMS,isomer #1 | CC(CC1=CC=C2OCOC2=C1)N[Si](C)(C)C(C)(C)C | 1859.3 | Standard non polar | 33892256 | | 3,4-Methylenedioxyamphetamine,2TBDMS,isomer #1 | CC(CC1=CC=C2OCOC2=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2289.7 | Semi standard non polar | 33892256 | | 3,4-Methylenedioxyamphetamine,2TBDMS,isomer #1 | CC(CC1=CC=C2OCOC2=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2331.2 | Standard non polar | 33892256 |
|
|---|